-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In the third quarter of 2021, Hillhouse carried out a large-scale adjustment of its warehouses, but the top three major warehouses were all biopharmaceutical companies, namely BeiGene, Legendary Bio and Tianjing Bio
.
According to data from the SEC website, the total market value of its holdings is as high as US$3.
065 billion (approximately RMB 19.
5 billion)
.
Among them, BeiGene has always been a "good heart" in Hillhouse's eyes.
In the third quarter of this year, BeiGene is still a major position in Hillhouse's US stocks
.
In the F13 documents for the third quarter, BeiGene became a major position in Hillhouse's stock holdings, holding 5,472,300 shares, corresponding to a market value of US$1.
986 billion
.
Industry insiders believe that in the field of innovative drugs, BeiGene's ability to obtain both FDA and NMPA certification at the same time, as well as the commercialization capabilities of cooperating with international giants, may be the reason why Hillhouse is determined to invest in BeiGene
.
It is understood that BeiGene was overweighted by Hillhouse before it went public
.
Public data shows that Hillhouse has participated in 8 rounds of financing of BeiGene since the 2014 A round
.
In BeiGene's Series A financing, Hillhouse and CPE Yuanfeng Capital entered together.
In May 2015, BeiGene launched a Series B financing, and Hillhouse and CPE Yuanfeng Capital appeared again
.
After BeiGene went public, Hillhouse has increased its positions many times
.
For example, in the fourth quarter of 2018, Hillhouse bought 2.
416 million shares of BeiGene in the secondary market
.
On July 13, 2020, BeiGene placed 146 million new shares, raising US$2.
08 billion
.
Hillhouse subscribed for a share of no less than US$1 billion (approximately RMB 7 billion)
.
It is understood that BeiGene was established in 2010, focusing on the development and commercialization of innovative molecular targeting and tumor immune drugs for the treatment of cancer
.
The data shows that since BeiGene was listed on the US stock market in 2016, its stock price has not fallen in a year, from 28.
97 US dollars per share all the way up to today's 380.
13 US dollars per share
.
As of November 18, BeiGene’s stock price has risen 47.
11% this year.
.
In the past two years, Hillhouse has made frequent actions in the primary and secondary markets.
Among them, it has a special liking for the pharmaceutical sector.
In addition to its long-term love for BeiGene, Hillhouse has also increased its positions in Legendary Bio in the third quarter of this year.
SEC data shows, In the third quarter of this year, Hillhouse added 10.
4 million shares to Legend Bio, making it jump to the second largest stock, holding 11.
05 million shares and holding a market value of 559 million U.
S.
dollars
.
According to the data, Legend Bio is mainly engaged in the development of antigen receptor T cell therapy.
Its parent company is GenScript Bio, a "global gene synthesis company", and Hillhouse has a layout before
.
On October 19th, Legend Bio announced its clinical stage and preclinical pipeline and key projects at its R&D day event, including 11 cell therapies
.
Data shows that at the end of the first quarter of this year, Legendary Bio started to bottom out and rebound.
The stock price rose 41% in the second quarter and continued to rise by 23% in the third quarter.
The increase during the year was as high as 74%, out of a wave of bull market
.
As for Tianjing Biology, in the third quarter, Hillhouse added 566,700 shares of Tianjing Biology, which jumped from the four largest stocks at the end of the second quarter to the top three largest stocks in Hillhouse US stocks
.
According to data, Tianjing Bio is an innovative biopharmaceutical company in the clinical stage, focusing on the early detection of innovative biological drugs in the field of immunity and autoimmune diseases.
Since the beginning of this year, Tianjing Bio's share price has risen by 28.
93%
.
It is reported that Tianjing Biology has three generations of iterative innovative antibodies
.
The first generation is a differentiated monoclonal antibody, such as CD47 and CD73 antibodies, which are currently undergoing phase II clinical trials in China and the United States; the second generation is a dual-target antibody with structural innovation, such as Claudin 18.
2 x 4-1BB double antibody, progressing Kuaidi's two double-antibody products have also entered Phase I clinical studies in the United States; the third generation is based on mRNA, AI and other platform technologies to build super antibodies
.
.
According to data from the SEC website, the total market value of its holdings is as high as US$3.
065 billion (approximately RMB 19.
5 billion)
.
Among them, BeiGene has always been a "good heart" in Hillhouse's eyes.
In the third quarter of this year, BeiGene is still a major position in Hillhouse's US stocks
.
In the F13 documents for the third quarter, BeiGene became a major position in Hillhouse's stock holdings, holding 5,472,300 shares, corresponding to a market value of US$1.
986 billion
.
Industry insiders believe that in the field of innovative drugs, BeiGene's ability to obtain both FDA and NMPA certification at the same time, as well as the commercialization capabilities of cooperating with international giants, may be the reason why Hillhouse is determined to invest in BeiGene
.
It is understood that BeiGene was overweighted by Hillhouse before it went public
.
Public data shows that Hillhouse has participated in 8 rounds of financing of BeiGene since the 2014 A round
.
In BeiGene's Series A financing, Hillhouse and CPE Yuanfeng Capital entered together.
In May 2015, BeiGene launched a Series B financing, and Hillhouse and CPE Yuanfeng Capital appeared again
.
After BeiGene went public, Hillhouse has increased its positions many times
.
For example, in the fourth quarter of 2018, Hillhouse bought 2.
416 million shares of BeiGene in the secondary market
.
On July 13, 2020, BeiGene placed 146 million new shares, raising US$2.
08 billion
.
Hillhouse subscribed for a share of no less than US$1 billion (approximately RMB 7 billion)
.
It is understood that BeiGene was established in 2010, focusing on the development and commercialization of innovative molecular targeting and tumor immune drugs for the treatment of cancer
.
The data shows that since BeiGene was listed on the US stock market in 2016, its stock price has not fallen in a year, from 28.
97 US dollars per share all the way up to today's 380.
13 US dollars per share
.
As of November 18, BeiGene’s stock price has risen 47.
11% this year.
.
In the past two years, Hillhouse has made frequent actions in the primary and secondary markets.
Among them, it has a special liking for the pharmaceutical sector.
In addition to its long-term love for BeiGene, Hillhouse has also increased its positions in Legendary Bio in the third quarter of this year.
SEC data shows, In the third quarter of this year, Hillhouse added 10.
4 million shares to Legend Bio, making it jump to the second largest stock, holding 11.
05 million shares and holding a market value of 559 million U.
S.
dollars
.
According to the data, Legend Bio is mainly engaged in the development of antigen receptor T cell therapy.
Its parent company is GenScript Bio, a "global gene synthesis company", and Hillhouse has a layout before
.
On October 19th, Legend Bio announced its clinical stage and preclinical pipeline and key projects at its R&D day event, including 11 cell therapies
.
Data shows that at the end of the first quarter of this year, Legendary Bio started to bottom out and rebound.
The stock price rose 41% in the second quarter and continued to rise by 23% in the third quarter.
The increase during the year was as high as 74%, out of a wave of bull market
.
As for Tianjing Biology, in the third quarter, Hillhouse added 566,700 shares of Tianjing Biology, which jumped from the four largest stocks at the end of the second quarter to the top three largest stocks in Hillhouse US stocks
.
According to data, Tianjing Bio is an innovative biopharmaceutical company in the clinical stage, focusing on the early detection of innovative biological drugs in the field of immunity and autoimmune diseases.
Since the beginning of this year, Tianjing Bio's share price has risen by 28.
93%
.
It is reported that Tianjing Biology has three generations of iterative innovative antibodies
.
The first generation is a differentiated monoclonal antibody, such as CD47 and CD73 antibodies, which are currently undergoing phase II clinical trials in China and the United States; the second generation is a dual-target antibody with structural innovation, such as Claudin 18.
2 x 4-1BB double antibody, progressing Kuaidi's two double-antibody products have also entered Phase I clinical studies in the United States; the third generation is based on mRNA, AI and other platform technologies to build super antibodies
.
